Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.08), $0.10 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $41.49 million versus the consensus estimate of $37.9 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.